Mechanism-based engineering against anthracycline cardiotoxicity

Circulation

Volumn 128, Issue 2, 2013, Pages 98-100

  Force, Thomas ^a   Wang, Yibin ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; RAZOXANE; REACTIVE OXYGEN METABOLITE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DEATH; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; EDITORIAL; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SARCOMERE; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR GROWTH;

DNA TOPOISOMERASES, TYPE II; DOXORUBICINE; EDITORIALS; LIGANDS; NEOPLASMS; NEUREGULIN-BETA; STROKE;

ANIMALS; CARDIOTONIC AGENTS; CHEMICAL ENGINEERING; DOXORUBICIN; FEMALE; HUMANS; MALE; MYOCYTES, CARDIAC; NEUREGULIN-1;

EID: 84880117174     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003688     Document Type: Editorial

References (18)

1. Dimarco A, Gaetani M, Orezzi P, Scarpinato BM, Silvestrini R, Soldati M, Dasdia T, Valentini L. "Daunomycin": A new antibiotic of the rhodomycin group. Nature. 1964;201:706-707
2. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717 (Pubitemid 10218041)
3. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003;97:2869-2879 (Pubitemid 36605157)
4. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-815
5. Chen MH, Colan SD, Diller L. Cardiovascular disease: Cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011;108:619-628
6. Jacot W, Fiche M, Zaman K, Wolfer A, Lamy PJ. The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond. Biochim Biophys Acta. 2013;1836:146-157
7. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nat Rev Cardiol. 2010;7:564-575
8. Christodoulou C, Kostopoulos I, Kalofonos HP, Lianos E, Bobos M, Briasoulis E, Gogas H, Razis E, Skarlos DV, Fountzilas G; Study of the Hellenic Cooperative Oncology Group. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer: Phase II study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology. 2009;76:275-285
9. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52:1213-1225
10. Geisberg C, Pentassuglia L, Sawyer DB. Cardiac side effects of anticancer treatments: New mechanistic insights. Curr Heart Fail Rep. 2012;9:211-218
11. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM. Antioxidants and cancer therapy: A systematic review. J Clin Oncol. 2004;22:517-528 (Pubitemid 41079781)
12. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639-1642
13. Jay SM, Murthy AC, Hawkins JF, Wortzel JR, Steinhauser ML, Alvarez LM, Gannon J, Macrae CA, Griffith LG, Lee RT. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation. 2013;128:152-161
14. Hasinoff BB, Herman EH. Dexrazoxane: How it works in cardiac and tumor cells: Is it a prodrug or is it a drug? Cardiovasc Toxicol. 2007;7:140-144 (Pubitemid 47339861)
15. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase IIbeta mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67:8839-8846 (Pubitemid 47437460)
16. Yan X, Morgan JP. Neuregulin1 as novel therapy for heart failure. Curr Pharm Des. 2011;17:1808-1817
17. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: Potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105:1551-1554 (Pubitemid 34297631)
18. Jay SM, Kurtagic E, Alvarez LM, de Picciotto S, Sanchez E, Hawkins JF, Prince RN, Guerrero Y, Treasure CL, Lee RT, Griffith LG. Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. J Biol Chem. 2011;286:27729-27740